Neurology: 健康相关生活质量(HRQOL)受损比传统的残疾量表更敏感

2016-01-24 phylis 译 MedSci原创

目的:研究者应用神经-QOL这项炎症患者预后的检查系统,调查了TIA患者轻微缺血性卒中患者(MIS)的健康相关生活质量(HRQOL)。方法:招募TIA或MIS患者(1)基线mRS分数0或1分,(2)初始NIHSS≤5,(3)无急性再灌注治疗(4)3个月的随访。记录复发性卒中,mRS和Barthel指数,神经QOL。研究者评估HRQOL受损的患者,应用Logistic回归分析受损HRQOL的预测因子

目的:研究者应用神经-生活质量这项被验证的患者报告预后的测量系统,调查了TIA患者中轻微缺血性卒中患者(MIS)的健康相关生活质量(HRQOL)。

方法:招募TIA或MIS患者(1)基线mRS分数0或1分,(2)初始NIHSS≤5,(3)无急性再灌注治疗,(4)3个月的随访。记录复发性卒中、mRS和Barthel指数、Neuro-QOL分数。研究者评估HRQOL受损的患者,应用Logistic回归分析受损HRQOL的预测因子。

结果:332例符合研究标准的患者(平均年龄65.7岁,52.4%为男性),90天内47例(14.2%)出现复发性卒中,41例(12.3%)3个月内残疾(MRS > 1或Barthel指数<95)。任何HRQOL损害者有119例(35.8%)。在多变量分析中,年龄(校正OR: 1.02,95% CI: 1.01-1.04)、初始NIHSS(OR 1.39,95% CI 1.17-1.64)、复发性卒中(OR 2.10,95% CI 1.06-4.13)和代理报告(OR 3.94,95% CI 1.54-10.10)是3个月受损HRQOL的独立预测因子。

结论: HRQOL受损通常发生在MIS和TIA发作后3个月内。HRQOL受损的预测因子包括年龄、卒中的严重程度和复发性卒中。未来的研究应该包括在预后评估里测量HRQOL,因为这可能比传统的残疾量表更敏感。

原文出处:

Sangha RS, Caprio FZ, et al.  Quality of life in patients with TIA and minor ischemic stroke. Neurology. 2015 Dec 1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1699490, encodeId=361916994907a, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Mon Oct 24 02:06:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999649, encodeId=1ae2199964990, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 31 03:06:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522179, encodeId=952a15221e964, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539257, encodeId=487a153925eb2, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-10-24 lancelotzzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1699490, encodeId=361916994907a, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Mon Oct 24 02:06:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999649, encodeId=1ae2199964990, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 31 03:06:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522179, encodeId=952a15221e964, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539257, encodeId=487a153925eb2, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-05-31 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1699490, encodeId=361916994907a, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Mon Oct 24 02:06:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999649, encodeId=1ae2199964990, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 31 03:06:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522179, encodeId=952a15221e964, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539257, encodeId=487a153925eb2, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1699490, encodeId=361916994907a, content=<a href='/topic/show?id=8ce7149e209' target=_blank style='color:#2F92EE;'>#QOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14972, encryptionId=8ce7149e209, topicName=QOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05b029929630, createdName=lancelotzzl, createdTime=Mon Oct 24 02:06:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999649, encodeId=1ae2199964990, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 31 03:06:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522179, encodeId=952a15221e964, content=<a href='/topic/show?id=d08e2e894e7' target=_blank style='color:#2F92EE;'>#健康相关生活质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27894, encryptionId=d08e2e894e7, topicName=健康相关生活质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd0411427202, createdName=yilong5287546, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539257, encodeId=487a153925eb2, content=<a href='/topic/show?id=294e911680' target=_blank style='color:#2F92EE;'>#HRQOL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9116, encryptionId=294e911680, topicName=HRQOL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2613125915, createdName=pyaili, createdTime=Tue Jan 26 04:06:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 pyaili

相关资讯

Stroke:短暂性脑缺血发作的症状及处理:男女有别?

背景和目的:短暂性脑缺血发作的存在,管理及预后是否存在性别差异,尚不清楚。方法:研究者进行了一项队列研究,在2003年7月1号到2008年3月31号期间,入住加拿大,安大略湖的11卒中中心的TIA患者5991名,比较男性和女性发生的症状,护理的过程及预后。研究者应用管理数据库的联系评估患者最初症状发生后30天及1年的死亡率及血管事件的再发,校正年龄和共发病,应用多变量分析评估是否存在性别差异。结果

JAMA Neurol:警惕以“短暂性脑缺血发作”为症状的“脑出血”

脑出血(ICH)患者可能会出现短暂性脑缺血发作(TIA)类似症状。缺乏脑部影像学检查时,小的脑出血所表现出的症状与TIA很难区分开来。该类患者应进行影像学检查,在CT或MRI排除脑出血之前,不应该进行抗血栓药物的治疗。通常情况下ICH患者随着事件推移会出现神经功能缺损。恶心、呕吐、意识障碍和显著的高血压是常见的表现特征。不过最近的一名左侧颞叶出血表现出短暂的语言障碍,症状疑是TIA。研究者对213

Stroke:决定短暂性脑缺血发作和卒中后痴呆风险的方法学因素

队列研究和实验性研究中的认知结果经常仅来源于面对面的临床评估。然而,认知障碍与发病率和死亡率的增加关系十分密切,导致较为严重的临床失访。在缺乏先前以人群为基础的数据的情况下,我们希望明确在检测短暂性脑缺血发作和卒中后痴呆风险时的损耗作用。研究方法:我们招募了2002年至2007年进入牛津血管(OXVASC)研究的短暂性脑缺血发作或卒中患者,对其临床和认知方面的基线数据进行评估并随访至2014年。针

Stroke:急性缺血性卒中和短暂性脑缺血发作后身体活动的量化评估

这项研究的目的是应用加速度计量化评估以及描述缺血性卒中与短暂性脑缺血发作一周之内的患者肢体运动的量与模式。研究方法:总共有100名患有急性缺血性卒中或短暂性脑缺血发作的患者被选中使用我们的急性卒中单元可穿戴Actical加速度计,固定于手腕、脚踝和臀部不超过7天。试验对象主要为症状出现72小时内的患者。利用加速度计的输出结果来测量患者的运动量(AC)。此外,应用斯堪的那维亚卒中量表对患者日常状况进

全新中国缺血性脑卒中和短暂性脑缺血发作二级预防指南

血性脑卒中和短暂性脑缺血发作(transient ischemic attack,TIA)是最常见的脑血管病类型,我国脑卒中亚型中,近70%的患者为缺血性脑卒中。最新数据显示,我国缺血性脑卒中年复发率高达17.7%。有效的二级预防是减少复发和死亡的重要手段。 撰写组通过复习相关研究证据,结合中国国情和临床现状,征求各方意见并充分讨论达成共识,集体制定了《中国缺血性脑卒中和短暂性脑缺血发作

Int J Stroke:识别TIA新标志物——质谱分析法

背景:短暂性脑缺血(TIA)发作的临床诊断,在临床大夫之间有着较大的差异。找到可靠的识别短暂性脑缺血发作的生物标记有助于改善对患者的护理,并给予积极治疗。 目的:研究人员旨在应用质谱分析蛋白质组学识别血浆中TIA的新型生物标记物。方法:招募存在短暂性神经症状的患者。应用质谱分析蛋白质组学的方法测试患者脑缺血发生的生物标志物,这是一种识别潜在的蛋白质的无偏倚方法。在招募的患者中进行第二次前瞻性性的队